San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies

Ryan Cross

Senior Science Correspondent

Replicate Bioscience, a biotech startup designing next-generation mRNA vaccines to trigger stronger and longer-lasting immune responses, has begun its first clinical study, the San Diego …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis highlights overall M&A track record following MorphoSys impairment

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

San Diego biotech starts clin­i­cal study of self-repli­cat­ing RNA vac­cine for ra­bies

Senior Science Correspondent

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

San Diego biotech starts clinical study of self-replicating RNA vaccine for rabies